Needham & Company LLC Cuts Artivion (NYSE:AORT) Price Target to $32.00

Artivion (NYSE:AORT) had its price target lowered by Needham & Company LLC from $34.00 to $32.00 in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other research firms have also weighed in on AORT. JMP Securities reaffirmed a “market outperform” rating and set a $33.00 price target on shares of Artivion in a report on Tuesday, December 10th. Oppenheimer raised their price target on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Friday, November 8th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Artivion currently has an average rating of “Buy” and a consensus price target of $31.40.

Artivion Price Performance

Artivion stock opened at $25.38 on Tuesday. Artivion has a 52-week low of $18.38 and a 52-week high of $32.33. The firm has a fifty day moving average of $29.63 and a 200-day moving average of $27.81. The firm has a market capitalization of $1.06 billion, a P/E ratio of -1,268.85 and a beta of 1.75. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71.

Artivion (NYSE:AORT) last released its quarterly earnings data on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.51). Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. The business had revenue of $97.31 million during the quarter, compared to analyst estimates of $100.82 million. As a group, analysts predict that Artivion will post 0.37 EPS for the current year.

Insider Buying and Selling at Artivion

In other Artivion news, SVP Jean F. Holloway sold 8,070 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $30.12, for a total transaction of $243,068.40. Following the transaction, the senior vice president now directly owns 153,862 shares in the company, valued at $4,634,323.44. This represents a 4.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Andrew M. Green sold 7,618 shares of the stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $30.00, for a total transaction of $228,540.00. Following the transaction, the vice president now owns 33,503 shares in the company, valued at $1,005,090. This trade represents a 18.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 77,224 shares of company stock worth $2,162,330 in the last ninety days. 8.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Quarry LP lifted its position in shares of Artivion by 210.8% in the 3rd quarter. Quarry LP now owns 1,209 shares of the company’s stock worth $32,000 after buying an additional 820 shares during the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Artivion by 236.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock worth $32,000 after buying an additional 786 shares during the last quarter. R Squared Ltd bought a new position in shares of Artivion in the 4th quarter worth about $39,000. Arcadia Investment Management Corp MI bought a new position in shares of Artivion in the 4th quarter worth about $43,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Artivion in the 4th quarter worth about $64,000. 86.37% of the stock is currently owned by institutional investors.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.